CNTY-813, lead beta islet cell therapy program as a potential functional cure for type 1 diabetes, in Investigational New Drug (IND)-enabling studies; IND submission expected in 4Q 2026 to support ...
Full year SaaS revenue of $319.2 million, representing 38% year-over-year growth, 36% on a constant currency basisFull year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results